权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Humoral Immune Mechanisms of Acute and Chronic Neurologic Sequelae of COVID-19

COVID-19急慢性神经系统后遗症的体液免疫机制

基本信息

批准号：
10573297
负责人：
SAMUEL JEREMY PLEASURE
金额：
$ 62.95万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-02-15 至 2025-11-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10573297
关键词：
2019-nCoV Acute Adult Anatomy Animal Disease Models Animal Model Antibodies Antibody Repertoire Antigens Antiviral Agents Autoantibodies Autoantigens Autoimmune Autoimmune encephalitis Autoimmunity B-Lymphocytes Behavioral Assay Biological Assay Biological Markers Blood Brain COVID-19 COVID-19 complications COVID-19 patient Cell Separation Cells Central Nervous System Cerebrospinal Fluid Child Chronic Clinical Clinical Management Clinical Research Clonal Expansion Collaborations Complex Coronavirus Cross Reactions Data Detection Development Disease Encephalitis Encephalopathies Enrollment Epitope Mapping Functional disorder General Hospitals Generations Goals Guillain Barré Syndrome Hospitalization Human Humoral Immunities Immune Immune response Immunofluorescence Immunologic Immunoprecipitation Immunosuppression Immunotherapy Infection Inflammation Inflammatory Infrastructure Infusion procedures Laboratories Laboratory Finding Maintenance Maps Mass Spectrum Analysis Medical center Metagenomics Molecular Molecular Mimicry Monoclonal Antibodies Moods Multiple Sclerosis Mus Neuroanatomy Neurologic Neurologist Neuropathogenesis Nucleic Acids Outpatients Pathogenesis Pathogenicity Patients Pediatric Hospitals Peripheral Nervous System Personality Phage Display Phage ImmunoPrecipitation Sequencing Phenotype Plasma Cells Play Production Proteome Protocols documentation RNA Resolution Rodent Role SARS-CoV-2 antibody SARS-CoV-2 infection SARS-CoV-2 spike protein Sampling San Francisco Scientist Seminoma Sensitivity and Specificity Stains Steroids Syndrome Testing Tissues United States National Institutes of Health Universities Viral Viral Antibodies Virus Diseases Work acute flaccid myelitis adaptive immune response animal model development biobank biomarker identification brain tissue clinical care clinical center clinical phenotype clinically actionable cohort cross reactivity experimental study extracellular human coronavirus in vivo innovation insight men microbial monoclonal antibody production neural neuroinflammation neurologic sequelae of COVID-19 neuromechanism next generation sequencing novel novel coronavirus overexpression pathogenic autoantibodies pleasure post-COVID-19 prospective screening treatment strategy viral detection

项目摘要

PROJECT SUMMARY COVID-19 is associated with a growing number of peripheral and central nervous system complications. It has become clear that a subset of these syndromes, including acute necrotizing encephalopathy, steroid- responsive encephalitis and Guillain-Barré syndrome, are likely due to direct viral neuroinvasion and/or autoimmunity triggered by SARS-CoV-2. There is an urgent need to prospectively investigate the acute and chronic neurologic complications of COVID-19 and determine which syndromes are neuroinflammatory in origin. While anti-viral therapeutics are still being developed for SARS-CoV-2, autoimmune CNS conditions can be very responsive to immunosuppression. Thus, identifying biomarkers for a subset of COVID-19 patients with autoimmune CNS syndromes in particular could immediately impact clinical management. Over the past 8 years, a unique interdisciplinary team of neurologists and basic scientists at UCSF was formed to develop and deploy an integrated approach to rapidly identify microbial nucleic acid, anti-viral antibodies and anti-neural antibodies associated with encephalitis, with the explicit intent to discover and validate clinically actionable biomarkers in addition to uncovering the fundamental mechanisms of disease pathogenesis underlying these syndromes. The centerpiece of these efforts is an ongoing patient cohort called the NID (Neuroinflammatory Disease) cohort, consisting of patients with suspected infectious or inflammatory encephalitis. This cohort is now >1,400 patients referred by clinicians at UCSF and from other centers around the world. Already, this cohort has spurred the development of the first ever clinically validated cerebrospinal fluid metagenomic next-generation sequencing assay, the identification of a novel paraneoplastic autoimmune syndrome with important implications for men with seminoma and the identification of enteroviral CSF antibodies in children with acute flaccid myelitis. Here, we propose to adapt this existing clinical research and laboratory infrastructure to enroll and investigate the urgent question whether COVID-19 patients with ongoing neurologic sequelae have CNS inflammation. We will perform this work in collaboration with colleagues at the NIH, Yale University as well as at UCSF Medical Center, Zuckerberg San Francisco General Hospital and UCSF Benioff Children’s Hospital. Using our unique clinical and molecular approach, we will investigate this hypothesis through the following specific aims: Aim 1: Characterize autoantibodies in the CSF of COVID-19 patients with acute and chronic neurologic syndromes Aim 2: Identify CSF specific antibody repertoires in COVID-19 patients with neurologic complications using high-resolution SARS-CoV-2 proteome-wide antibody profiling Aim 3: Elucidate autoantibody pathogenicity through production of monoclonal antibodies from clonally expanded CSF B cells in COVID-19 patients to enable the development of animal models of disease

项目总结